Teva Gives Up Its Store-Brand OTC Portfolio To PLD
Teva’s US store-brand OTC portfolio including
You may also be interested in...
Teva is on track to achieve its targeted US$3 billion spending reduction by the end of 2019, according to president and chief executive officer Kåre Schultz. Ridding the firm of a number of its facilities and cutting staff by more than 9,000 has already produced efficiencies of US$1.8 billion in 2018.
Teva still sees OTC medicines as a “growing and long-term key business”, despite announcing plans with Procter & Gamble (P&G) to end the pair’s six-year ‘PGT Healthcare’ OTC joint venture, according to the Israeli firm. The decision – made after “the companies concluded that their priorities and strategies are no longer closely aligned” – comes as Teva is executing a major structural overhaul instigated by chief executive officer Kåre Schultz (Generics bulletin, 1 December 2017, page 1), and is “not expected to have a material impact on Teva’s 2018 financial outlook”.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.